by Peter Ciszewski | Oct 22, 2022
Ronald Martell, President, and CEO of Jasper Therapeutics, discusses the positive data from the ongoing phase 1/2 study testing JSP191 as a conditioning agent in the treatment of Fanconi anemia. These data were presented at the annual conference of the Inborn...
by Peter Ciszewski | Oct 19, 2022
Ricardo Dolmetsch, PhD, President of Research and Development at uniQure, discusses what he thinks physicians should know about gene therapy. Huntington disease is an inherited, neurodegenerative disorder that usually begins to be symptomatic starting at around...
by Peter Ciszewski | Oct 18, 2022
Evan S. Dellon, MD, MPH, Gastroenterologist, and Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, explains two things that physicians should know about eosinophilic esophagitis (EoE). EoE is a chronic,...
by Peter Ciszewski | Oct 17, 2022
Pam Vig, PhD, Head of Research & Development at Mirum Pharmaceuticals, discusses how the approval of maralixibat has changed the management of Alagille syndrome. Alagille syndrome is a genetic disorder that can affect the liver, heart, skeleton, eyes, and...
by Peter Ciszewski | Oct 13, 2022
Ajay K. Nooka, MD, Associate Professor of Hematology and Medical Oncology at Emory School of Medicine, discusses the current treatment landscape for multiple myeloma. Multiple myeloma is a rare blood cancer associated with uncontrolled growth of plasma cells....
